AU2007334248B2 - Devices and methods for ophthalmic drug delivery - Google Patents

Devices and methods for ophthalmic drug delivery Download PDF

Info

Publication number
AU2007334248B2
AU2007334248B2 AU2007334248A AU2007334248A AU2007334248B2 AU 2007334248 B2 AU2007334248 B2 AU 2007334248B2 AU 2007334248 A AU2007334248 A AU 2007334248A AU 2007334248 A AU2007334248 A AU 2007334248A AU 2007334248 B2 AU2007334248 B2 AU 2007334248B2
Authority
AU
Australia
Prior art keywords
styrene
eye
drug
subject
block copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007334248A
Other languages
English (en)
Other versions
AU2007334248A1 (en
Inventor
Bahram Asgharian
Masood A. Chowhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Research LLC filed Critical Alcon Research LLC
Publication of AU2007334248A1 publication Critical patent/AU2007334248A1/en
Application granted granted Critical
Publication of AU2007334248B2 publication Critical patent/AU2007334248B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007334248A 2006-12-18 2007-11-08 Devices and methods for ophthalmic drug delivery Ceased AU2007334248B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85814306P 2006-12-18 2006-12-18
US60/858,143 2006-12-18
PCT/US2007/084009 WO2008076544A2 (en) 2006-12-18 2007-11-08 Devices and methods for ophthalmic drug delivery

Publications (2)

Publication Number Publication Date
AU2007334248A1 AU2007334248A1 (en) 2008-06-26
AU2007334248B2 true AU2007334248B2 (en) 2013-06-27

Family

ID=39265276

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007334248A Ceased AU2007334248B2 (en) 2006-12-18 2007-11-08 Devices and methods for ophthalmic drug delivery

Country Status (13)

Country Link
US (2) US20080145406A1 (enExample)
EP (1) EP2091481A2 (enExample)
JP (1) JP5323720B2 (enExample)
KR (1) KR20090098870A (enExample)
CN (2) CN101563051A (enExample)
AR (1) AR063619A1 (enExample)
AU (1) AU2007334248B2 (enExample)
BR (1) BRPI0720431A2 (enExample)
CA (1) CA2670944A1 (enExample)
MX (1) MX2009006146A (enExample)
TW (1) TW200829293A (enExample)
WO (1) WO2008076544A2 (enExample)
ZA (1) ZA200903649B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP1658109B1 (en) 2003-08-26 2014-01-22 Vista Scientific LLC Ocular drug delivery device
PL1660057T3 (pl) * 2003-08-27 2012-10-31 Ophthotech Corp Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
WO2009064834A2 (en) 2007-11-13 2009-05-22 Maskin Steven L Meibomian gland intraductal diagnostic and treatment methods and related apparatus
US9510844B2 (en) 2007-11-13 2016-12-06 Mgd Innovations, Llc Gland or duct diagnostic and treatment methods and related apparatus
US9873001B2 (en) 2008-01-07 2018-01-23 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US10022558B1 (en) 2008-01-07 2018-07-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
EP2276439A4 (en) 2008-05-12 2013-11-27 Univ Utah Res Found DEVICE AND CORRESPONDING METHODS FOR INTRAOCULAR MEDICAMENT ADMINISTRATION
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
TW201012469A (en) * 2008-06-24 2010-04-01 Qlt Plug Delivery Inc Combination treatment of glaucoma
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4 Inc Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US20100226962A1 (en) * 2009-03-03 2010-09-09 Rodstrom Theron R Peri-corneal drug delivery device
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2012071476A2 (en) 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
JP5695035B2 (ja) 2009-06-03 2015-04-01 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 前眼部薬物供給
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
HUE057267T2 (hu) 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
HUE054113T2 (hu) 2010-08-05 2021-08-30 Forsight Vision4 Inc Injekciós készülék gyógyszerbejuttatáshoz
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
BR112013018739A2 (pt) * 2010-12-29 2019-09-24 Jade Therapeutics Inc sistema de distribuição de medicamento ocular
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
WO2013040238A2 (en) 2011-09-13 2013-03-21 Vista Scientific Llc Sustained release ocular drug delivery devices and methods of manufacture
ES2912370T3 (es) 2011-09-14 2022-05-25 Forsight Vision5 Inc Aparato para inserción ocular
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
US9510972B2 (en) * 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US9642742B2 (en) 2012-10-02 2017-05-09 Harold D. Mansfield Eye drop applicator and drop transfer method
CN104884006B (zh) 2012-10-26 2017-12-15 弗赛特影像5股份有限公司 用于持续释放药物到眼睛的眼科系统
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
EP3148491B1 (en) 2014-05-29 2020-07-01 Glaukos Corporation Implants with controlled drug delivery features and manufacturing method for said implants
WO2016011191A1 (en) 2014-07-15 2016-01-21 Forsight Vision4, Inc. Ocular implant delivery device and method
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
ES2900025T3 (es) * 2014-09-06 2022-03-15 Integral Biosystems Llc Procedimientos y composiciones biocompatibles para lograr la liberación mantenida de fármaco en el ojo
BR112017009660A2 (pt) 2014-11-10 2017-12-19 Forsight Vision4 Inc dispositivos de administração de fármacos expansíveis e métodos de utilização
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2016187426A1 (en) 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
JP6912475B2 (ja) 2015-11-20 2021-08-04 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 持続放出性薬物送達機器用の多孔質構造体
AR108177A1 (es) 2016-04-05 2018-07-25 Forsight Vision4 Inc Dispositivos de suministro de fármacos oculares implantables
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
US10603210B1 (en) 2017-02-02 2020-03-31 Mgd Innovations, Llc Meibomian gland probing with blood product injection
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
EP3801462A4 (en) 2018-05-24 2022-03-16 Celanese EVA Performance Polymers LLC Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417527A (en) * 1972-12-27 1975-12-10 Alza Corp Sustained release dispensing device and method
US5476511A (en) * 1992-05-04 1995-12-19 Allergan, Inc. Subconjunctival implants for ocular drug delivery
US6413540B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Drug delivery device
WO2005057272A2 (en) * 2003-12-05 2005-06-23 Innfocus, Llc Improved ocular lens
US20050181015A1 (en) * 2004-02-12 2005-08-18 Sheng-Ping (Samuel) Zhong Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
WO1999046327A1 (en) * 1998-03-11 1999-09-16 The Dow Chemical Company STRUCTURES AND FABRICATED ARTICLES HAVING SHAPE MEMORY MADE FROM α-OLEFIN/VINYL OR VINYLIDENE AROMATIC AND/OR HINDERED ALIPHATIC VINYL OR VINYLIDENE INTERPOLYMERS
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
AU2001271417B2 (en) * 2000-08-30 2006-10-05 Johns Hopkins University Devices for intraocular drug delivery
CA2433032C (en) * 2001-01-03 2008-11-25 Bausch & Lomb Incorporated Sustained release drug delivery devices with coated drug cores
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
PL375024A1 (en) * 2002-08-05 2005-11-14 Alcon, Inc. Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
US20040219198A1 (en) * 2003-05-01 2004-11-04 3M Innovative Properties Company Transdermal drug delivery device with multilayer backing
WO2005055972A2 (en) * 2003-12-09 2005-06-23 Nanon A/S A drug delivery device and a method of producing it
US7541048B2 (en) * 2004-04-06 2009-06-02 Surmodics, Inc. Coating compositions for bioactive agents
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US20060257460A1 (en) * 2005-05-13 2006-11-16 Jansen Rolf R Multilayer drug delivery system with barrier against antagonist exposure
US10029034B2 (en) * 2005-12-15 2018-07-24 CARDINAL HEALTH SWITZERLAND 515 GmbH Drug-eluting articles with improved drug release profiles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417527A (en) * 1972-12-27 1975-12-10 Alza Corp Sustained release dispensing device and method
US5476511A (en) * 1992-05-04 1995-12-19 Allergan, Inc. Subconjunctival implants for ocular drug delivery
US6413540B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Drug delivery device
WO2005057272A2 (en) * 2003-12-05 2005-06-23 Innfocus, Llc Improved ocular lens
US20050181015A1 (en) * 2004-02-12 2005-08-18 Sheng-Ping (Samuel) Zhong Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SASAKI, H. et al. "Drug release from an ophthalmic insert of a beta-blocker as an ocular drug delivery system". November 1993, Journal of Controlled Release, Vol.27, Issue 2, Pages 127-137 *

Also Published As

Publication number Publication date
BRPI0720431A2 (pt) 2013-12-31
KR20090098870A (ko) 2009-09-17
MX2009006146A (es) 2009-06-19
JP2010513542A (ja) 2010-04-30
CN103622778A (zh) 2014-03-12
EP2091481A2 (en) 2009-08-26
US20100266664A1 (en) 2010-10-21
TW200829293A (en) 2008-07-16
ZA200903649B (en) 2010-08-25
AR063619A1 (es) 2009-02-04
CA2670944A1 (en) 2008-06-26
WO2008076544A3 (en) 2008-08-28
AU2007334248A1 (en) 2008-06-26
JP5323720B2 (ja) 2013-10-23
WO2008076544A2 (en) 2008-06-26
CN101563051A (zh) 2009-10-21
US20080145406A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
AU2007334248B2 (en) Devices and methods for ophthalmic drug delivery
Sadruddin et al. Ab externo implantation of the MicroShunt, a poly (styrene-block-isobutylene-block-styrene) surgical device for the treatment of primary open-angle glaucoma: a review
CN101984745B (zh) 用于持续释放治疗药物的药物核心
US8003124B2 (en) Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
AU2004237774B2 (en) Implantable controlled release bioactive agent delivery device
JP2022119912A (ja) ヒト被験体における眼部障害の処置のための方法およびデバイス
JP6602761B2 (ja) 眼科用デバイス
Sun et al. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL)
JP2016127945A (ja) １つまたは複数の薬剤の徐放性送達
US20070134244A1 (en) Combination treatment for pathologic ocular angiogenesis
JP2007500250A (ja) 病的な眼の新脈管形成を処置するための非ステロイド性抗炎症剤の処方物
JP2007500250A5 (enExample)
WO2025248489A1 (en) Bio-erodible ocular implants for treatment of conditions of the eye
JP2025506291A (ja) アイレット
HK1155104B (en) Drug cores for sustained release of therapeutic agents
AU2005229667A1 (en) Controlled release bioactive agent delivery device
ZA200509532B (en) Formulations or non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired